Nanomix Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNMX research report →
Companywww.bostonti.com
Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications.
- CEO
- David Gerald Ludvigson
- IPO
- 2021
- Employees
- 30
- HQ
- Lawrence, MA, US
Price Chart
Valuation
- Market Cap
- $9.80K
- P/E
- -0.00
- P/S
- 0.63
- P/B
- -0.00
- EV/EBITDA
- -1.40
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -449.57%
- Op Margin
- -54609.50%
- Net Margin
- -79825.09%
- ROE
- 128.37%
- ROIC
- 475.90%
Growth & Income
- Revenue
- $15.45K · -89.10%
- Net Income
- $-12,332,976 · -5.57%
- EPS
- $-0.00 · 99.99%
- Op Income
- $-8,437,168
- FCF YoY
- 8.13%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.36
- Avg Volume
- 25
Get TickerSpark's AI analysis on NNMX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 13, 22 | Hetterly Chris | other | 500,000 |
| Oct 11, 22 | SCHIFFMAN GREGORY T | other | 12,920 |
| Mar 2, 22 | SCHIFFMAN GREGORY T | other | 36,167 |
| Jun 4, 21 | SCHIFFMAN GREGORY T | other | 21,631,402 |
| Dec 9, 22 | GRUENER GARRETT | buy | 7,380 |
| Dec 9, 22 | GRUENER GARRETT | buy | 2,620 |
| Nov 28, 22 | GRUENER GARRETT | buy | 213,366 |
| Nov 10, 22 | GRUENER GARRETT | buy | 355,610 |
| Oct 11, 22 | GRUENER GARRETT | buy | 355,609 |
| Sep 9, 22 | GRUENER GARRETT | buy | 355,609 |
Our NNMX Coverage
We haven't published any research on NNMX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NNMX Report →